ISSN: 1859 - 2872
Current prophylaxis practices for chemotherapy-induced febrile neutropenia in breast cancer patients at the National Cancer Hospital
Main Article Content
Keywords
Abstract
Objective: To analyze the status and effectiveness of febrile neutropenia (FN) prophylaxis using granulocyte colony-stimulating factor (G-CSF) in breast cancer patients undergoing chemotherapy. Subject and method: A prospective cohort study was conducted on 219 breast cancer patients aged ≥ 18 years receiving chemotherapy at Departments of Internal Medicine 5 and 6, K Hospital, from January 1, 2024, to March 31, 2024. Result: The mean age was 50.4 ± 10.2 years. The proportion of patients receiving chemotherapy regimens with a high and intermediate risk of FN was 50.7% and 45.7%, respectively. Assessment of prophylaxis according to guideline recommendations showed: appropriate prophylaxis (52.0%), no prophylaxis appropriately indicated (29.2%), over-prophylaxis (15.1%), and under-prophylaxis (3.7%). Most patients received filgrastim (69.7%), with a duration of less than 5 days (95.1%). Thirty patients experienced neutropenia of any grade (13.7%), including 3 patients with severe neutropenia (1.4%). No patients developed FN. Multivariate analysis showed that among patients requiring prophylaxis, appropriate prophylaxis significantly reduced the risk of neutropenia (OR [95% CI]: 0.004 [0.020-0.771]; p=0.033) compared with under-prophylaxis. Among patients not requiring prophylaxis, over-prophylaxis was not significantly associated with neutropenia risk (p=0.418). Conclusion: Adequate G-CSF prophylaxis in accordance with guideline recommendations may provide benefits in reducing the incidence of neutropenia events.
Article Details
References
2. Bộ Y tế (2020) Hướng dẫn chẩn đoán và điều trị ung thư vú.
3. National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, ver 2.2024.
4. Lyman GH, Dale DC et al (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 21(24): 4524-4531.
5. Bộ Y tế (2019) Sốt và giảm bạch cầu trung tính trên bệnh nhân sử dụng hóa trị. Hướng dẫn thực hành lâm sàng cho dược sỹ trong một số bệnh không lây nhiễm, Nhà xuất bản Y học, Hà Nội, tr. 329-335.
6. Bộ Y tế (2020) Sốt do giảm bạch cầu ở bệnh nhân ung thư. Hướng dẫn chẩn đoán và điều trị một số bệnh Ung bướu, Nhà xuất bản Y học, Hà Nội, tr. 26-34.
7. National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 3.2024".
8. Trần Thị Thu Trang (2020) Phân tích việc dự phòng và xử trí biến cố giảm bạch cầu trung tính do hóa trị liệu trên bệnh nhân ung thư vú và u lympho tại Bệnh viện K. Tạp chí Y học Việt Nam, 488(2) tr. 225-230.
9. Bộ Y tế (2019) Hướng dẫn thực hành dược lâm sàng cho Dược sỹ trong một số bệnh không lây nhiễm.
10. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1): 8-32.
11. Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28): 3199-3212.
12. Weycker D, Bensink M et al (2019) Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: A longitudinal assessment. Curr Med Res Opin 35(6): 1073-1080.
13. Weycker D, Barron R et al (2014) Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: The importance of duration of prophylaxis. BMC Health Serv Res 14: 189.
Article Sidebar
